ARIA-H <10 mm proportional hazards models, HRs and 95% CIs
| Reduced model (1) | Reduced model (2) | Full model | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| LL | UL | LL | UL | LL | UL | ||||
| Placebo (referent) | 1.00 | 1.00 | 1.00 | ||||||
| Dose 0.15 mg/kg | 2.78 | 0.64 | 12.16 | 3.66 | 0.95 | 14.16 | |||
| Dose 0.5 mg/kg | 4.13 | 1.09 | 15.74 | 2.64 | 0.62 | 11.20 | |||
| Dose 1.0 mg/kg | 2.33 | 0.57 | 9.47 | 7.04 | 1.62 | 30.65 | |||
| Dose 2.0 mg/kg | 6.19 | 1.56 | 24.52 | 2.46 | 0.50 | 12.22 | |||
| Active | 3.54 | 1.05 | 11.96 | ||||||
| No APOE ε4 allele (referent) | 1.00 | 1.00 | 1.00 | ||||||
| APOE ε4 1 vs none | 4.10 | 1.16 | 14.53 | 3.63 | 1.04 | 12.70 | 4.16 | 1.09 | 15.91 |
| APOE ε4 2 vs none | 12.79 | 3.58 | 45.76 | 11.89 | 3.33 | 42.50 | 14.79 | 3.92 | 55.74 |
| No antithrombotic use (referent) | 1.00 | 1.00 | 1.00 | ||||||
| Antithrombotic use | 2.20 | 0.99 | 4.89 | 2.19 | 1.00 | 4.76 | 2.11 | 0.86 | 5.19 |
| No ARIA-H <10 mm at baseline (referent) | 1.00 | 1.00 | 1.00 | ||||||
| ARIA-H <10 mm versus none | 3.58 | 1.59 | 8.06 | 3.46 | 1.56 | 7.67 | 3.98 | 1.53 | 10.31 |
| Hamilton Psychiatric Rating Scale for Depression score ≤2 at baseline (referent) | 1.0 | ||||||||
| Hamilton Psychiatric Rating Scale for Depression score >2 | 0.71 | 0.27 | 1.88 | ||||||
| Modified Hachinski score ≤0.5 at baseline (referent) | 1.00 | ||||||||
| Modified Hachinski score >0.5 | 1.69 | 0.75 | 3.82 | ||||||
| Male (referent) | 1.00 | ||||||||
| Female | 0.60 | 0.26 | 1.37 | ||||||
| White (referent) | 1.00 | ||||||||
| Non-white | 0.31 | 0.06 | 1.63 | ||||||
| Age (in year) | 1.00 | 0.95 | 1.05 | ||||||
| MMSE score | 0.97 | 0.88 | 1.07 | ||||||
| Not hypertensive (referent) | 1.00 | ||||||||
| Hypertensive | 0.64 | 0.26 | 1.59 | ||||||
| White Matter Hyperintensity Scale score (0, 1) (referent) | 1.00 | ||||||||
| White Matter Hyperintensity Scale score (2, 3) | 1.83 | 0.63 | 5.37 | ||||||
| No ARIA-E at baseline (referent) | 1.00 | ||||||||
| ARIA-E at baseline | 0.94 | 0.09 | 9.82 | ||||||
Reduced model (1) includes assigned bapineuzumab dose in mg/kg as a categorical variable.
Reduced model (2) includes assigned bapineuzumab dose as a single category.
Hypertension is defined by the use of an antihypertensive therapy, systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg.
ARIA-E, amyloid-related imaging abnormalities-edema; ARIA-H, ARIA-haemosiderin; LL, lower limit; MMSE, Mini-Mental State Examination; UL, upper limit.